KR101215164B1 - 신규 시클로펜타〔ｂ〕벤조푸란 유도체 및 이의 용도 - Google Patents
신규 시클로펜타〔ｂ〕벤조푸란 유도체 및 이의 용도 Download PDFInfo
- Publication number
- KR101215164B1 KR101215164B1 KR1020067024170A KR20067024170A KR101215164B1 KR 101215164 B1 KR101215164 B1 KR 101215164B1 KR 1020067024170 A KR1020067024170 A KR 1020067024170A KR 20067024170 A KR20067024170 A KR 20067024170A KR 101215164 B1 KR101215164 B1 KR 101215164B1
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- hydrogen
- formula
- alkyl
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 **1C=CC(C(C(CC=O)C2=CC=C*C=C2)(C2=O)Oc3c2c(*)cc(*)c3)=CCC1 Chemical compound **1C=CC(C(C(CC=O)C2=CC=C*C=C2)(C2=O)Oc3c2c(*)cc(*)c3)=CCC1 0.000 description 8
- LPWVWUAUBZMPEV-SISXCUBESA-N CC(/C=C(\C=C(/C[C@@]1([C@@H](C[C@H]2c3ccccc3)O)O)\O[C@]12c(cc1)ccc1Cl)/OCCN(C)C)OCCN(C)C Chemical compound CC(/C=C(\C=C(/C[C@@]1([C@@H](C[C@H]2c3ccccc3)O)O)\O[C@]12c(cc1)ccc1Cl)/OCCN(C)C)OCCN(C)C LPWVWUAUBZMPEV-SISXCUBESA-N 0.000 description 1
- JSPNXHBBLKLOBC-UHFFFAOYSA-N CC(C)(C)[Si+](C)(C)Oc(c(c([o]1)ccc2)c2OCCOC)c1Br Chemical compound CC(C)(C)[Si+](C)(C)Oc(c(c([o]1)ccc2)c2OCCOC)c1Br JSPNXHBBLKLOBC-UHFFFAOYSA-N 0.000 description 1
- GVPLYMYKDDSLCT-UHFFFAOYSA-N CC(C)(C)[Si+](C)(C)Oc1c(-c(cc2)ccc2Cl)[o]c2cc(OCCCl)ccc12 Chemical compound CC(C)(C)[Si+](C)(C)Oc1c(-c(cc2)ccc2Cl)[o]c2cc(OCCCl)ccc12 GVPLYMYKDDSLCT-UHFFFAOYSA-N 0.000 description 1
- JHUBNQSPUZXGKI-UHFFFAOYSA-N CC(C)c(cc1)cc2c1OCO2 Chemical compound CC(C)c(cc1)cc2c1OCO2 JHUBNQSPUZXGKI-UHFFFAOYSA-N 0.000 description 1
- ALIIAYWLXQCOJB-UHFFFAOYSA-N CC(Nc1ccc(C(CO2)=O)c2c1)=O Chemical compound CC(Nc1ccc(C(CO2)=O)c2c1)=O ALIIAYWLXQCOJB-UHFFFAOYSA-N 0.000 description 1
- MJBGVIAJSIPLCJ-UHFFFAOYSA-N CCOc1cc(OCC)cc(OC(C(OC)=O)c(cc2)ccc2Br)c1 Chemical compound CCOc1cc(OCC)cc(OC(C(OC)=O)c(cc2)ccc2Br)c1 MJBGVIAJSIPLCJ-UHFFFAOYSA-N 0.000 description 1
- QLPJAJRIZUIEIG-KFHCRBHPSA-N CCOc1cc(O[C@@](C([C@@H](C(N(C)C)O)C2=O)c3ccccc3)([C@@]22O)c(cc3)ccc3Cl)c2c(OCC)c1 Chemical compound CCOc1cc(O[C@@](C([C@@H](C(N(C)C)O)C2=O)c3ccccc3)([C@@]22O)c(cc3)ccc3Cl)c2c(OCC)c1 QLPJAJRIZUIEIG-KFHCRBHPSA-N 0.000 description 1
- ZADDSXHZFZYIAG-TUSQITKMSA-N CCOc1cc(O[C@@]([C@@H](CC2=O)c3ccccc3)([C@@]22O)c(cc3)ccc3Cl)c2cc1 Chemical compound CCOc1cc(O[C@@]([C@@H](CC2=O)c3ccccc3)([C@@]22O)c(cc3)ccc3Cl)c2cc1 ZADDSXHZFZYIAG-TUSQITKMSA-N 0.000 description 1
- WKFYSRLTBVKWSO-CLWCVJJRSA-N CCOc1cc(O[C@@]([C@@H](C[C@H]2O)c3ccccc3)([C@@]22O)c(cc3)ccc3-c3cc(N)ccc3F)c2c(OCC)c1 Chemical compound CCOc1cc(O[C@@]([C@@H](C[C@H]2O)c3ccccc3)([C@@]22O)c(cc3)ccc3-c3cc(N)ccc3F)c2c(OCC)c1 WKFYSRLTBVKWSO-CLWCVJJRSA-N 0.000 description 1
- GMCQCASFDPJWDQ-ZTNKVBRBSA-N C[C@H](C[C@H]([C@]1(c(cc2)ccc2[NH-])Oc2c3ccc(OCN)c2)c2ccccc2)[C@]13OC Chemical compound C[C@H](C[C@H]([C@]1(c(cc2)ccc2[NH-])Oc2c3ccc(OCN)c2)c2ccccc2)[C@]13OC GMCQCASFDPJWDQ-ZTNKVBRBSA-N 0.000 description 1
- FBPCNJIGBKWCMR-UHFFFAOYSA-N O=C(C(Oc1ccc2)Br)c1c2OCCCl Chemical compound O=C(C(Oc1ccc2)Br)c1c2OCCCl FBPCNJIGBKWCMR-UHFFFAOYSA-N 0.000 description 1
- PTWXVGGQJDPHQJ-CPJSRVTESA-N O=CC[C@H]([C@]1(c(cc2)ccc2Cl)Oc2cccc(OCCCl)c2C1=O)c1ccccc1 Chemical compound O=CC[C@H]([C@]1(c(cc2)ccc2Cl)Oc2cccc(OCCCl)c2C1=O)c1ccccc1 PTWXVGGQJDPHQJ-CPJSRVTESA-N 0.000 description 1
- ZVMAIEAUQCWTHD-RQJMDQOWSA-N O[C@@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3ccc(NC(c(cccn4)c4F)=O)c2)c2ccccc2)[C@]13O Chemical compound O[C@@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3ccc(NC(c(cccn4)c4F)=O)c2)c2ccccc2)[C@]13O ZVMAIEAUQCWTHD-RQJMDQOWSA-N 0.000 description 1
- ZHJSXTBXKRSWPT-CKLFDVLTSA-N O[C@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3c(OCCN4CCCC4)ccc2)c2ccccc2)[C@]13O Chemical compound O[C@H](C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3c(OCCN4CCCC4)ccc2)c2ccccc2)[C@]13O ZHJSXTBXKRSWPT-CKLFDVLTSA-N 0.000 description 1
- IERFQVQOSLUXTN-UHFFFAOYSA-N Oc1cc(OCCCl)cc(OCCCl)c1 Chemical compound Oc1cc(OCCCl)cc(OCCCl)c1 IERFQVQOSLUXTN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004024504.5 | 2004-05-18 | ||
| DE102004024504A DE102004024504A1 (de) | 2004-05-18 | 2004-05-18 | Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung |
| PCT/EP2005/005298 WO2005113529A2 (de) | 2004-05-18 | 2005-05-14 | Neue cylopenta[b]benzofuran-derivate und ihre verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20070011522A KR20070011522A (ko) | 2007-01-24 |
| KR101215164B1 true KR101215164B1 (ko) | 2012-12-24 |
Family
ID=35207782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067024170A Expired - Fee Related KR101215164B1 (ko) | 2004-05-18 | 2006-11-17 | 신규 시클로펜타〔ｂ〕벤조푸란 유도체 및 이의 용도 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8030347B2 (https=) |
| EP (1) | EP1751127B1 (https=) |
| JP (1) | JP2007538031A (https=) |
| KR (1) | KR101215164B1 (https=) |
| CN (1) | CN1989122B (https=) |
| AU (1) | AU2005245104B2 (https=) |
| BR (1) | BRPI0510403A (https=) |
| CA (1) | CA2567404C (https=) |
| DE (1) | DE102004024504A1 (https=) |
| IL (1) | IL179257A (https=) |
| MX (1) | MXPA06013182A (https=) |
| RU (1) | RU2415847C9 (https=) |
| WO (1) | WO2005113529A2 (https=) |
| ZA (1) | ZA200609444B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1771169A1 (en) | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Methods for treating hepatitis c |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| EP1693059A1 (en) * | 2005-02-22 | 2006-08-23 | Deutsches Krebsforschungszentrum | Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases |
| EP2189453A1 (en) * | 2008-11-25 | 2010-05-26 | Université Louis Pasteur | Rocaglaol derivatives as cardioprotectant agents |
| EP2457907A1 (en) * | 2010-11-16 | 2012-05-30 | Université de Strasbourg | Flavagline derivatives as neuroprotective agents |
| US20140255432A1 (en) * | 2011-07-27 | 2014-09-11 | Ohio State Innovation Foundation | Silvestrol, silvestrol analogs and uses thereof |
| FR3023290B1 (fr) * | 2014-07-04 | 2016-08-19 | Pf Medicament | Derives de flavaglines |
| EP3888658B1 (en) | 2015-11-25 | 2023-12-27 | Effector Therapeutics, Inc. | Eif4-a-inhibiting compounds and methods related thereto |
| EP3755693B1 (en) | 2018-02-19 | 2024-06-12 | Memorial Sloan-Kettering Cancer Center | Agents and methods for treating dysproliferative diseases |
| EP3639820A1 (en) | 2018-10-16 | 2020-04-22 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Flavagline derivatives for inhibition of kras oncogene activation |
| CN110646616B (zh) * | 2019-09-05 | 2023-05-30 | 桂林理工大学 | 一种检测血清中人cTnI的超敏荧光猝灭免疫传感器及检测方法 |
| CN110776486B (zh) * | 2019-10-23 | 2022-05-20 | 中国药科大学 | 一种苯并呋喃类小分子p2y14受体抑制剂，及其制备和应用 |
| CA3230542A1 (en) | 2021-09-01 | 2023-03-09 | Krishnaraj Rajalingam | Novel ras inhibitors |
| CN116077483A (zh) * | 2021-11-05 | 2023-05-09 | 上海中医药大学 | 楝酰胺及其类似物的药物用途 |
| CN115385924B (zh) * | 2022-10-06 | 2023-10-13 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用 |
| WO2024175662A1 (en) | 2023-02-23 | 2024-08-29 | KHR Biotec GmbH | Flavagline derivatives as ras inhibitors |
| JP2026508161A (ja) | 2023-02-23 | 2026-03-10 | エスジェーピー バイオテック ゲーエムベーハー | 新規ＲＡＳ阻害剤３ａＨ－シクロペンタ［ｂ］ベンゾフラン－３ａ－イル |
| WO2025092976A1 (zh) * | 2023-11-03 | 2025-05-08 | 映恩生物制药（苏州）有限公司 | 蛋白翻译抑制剂 |
| TW202545938A (zh) * | 2024-01-16 | 2025-12-01 | 大陸商映恩生物製藥（蘇州）有限公司 | 一種蛋白轉譯抑制劑的偶聯物及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000007579A2 (de) * | 1998-08-05 | 2000-02-17 | Bayer Aktiengesellschaft | VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN |
| WO2000008007A2 (de) * | 1998-08-05 | 2000-02-17 | Bayer Aktiengesellschaft | Cyclopentabenzofuran-derivate und ihre verwendung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU191264B (en) * | 1984-01-13 | 1987-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for production of derivatives of 7-oxo-prostacyclin with selective biological effect |
| KR100381584B1 (ko) * | 1994-07-22 | 2003-08-21 | 알타나 파마 아게 | 디히드로벤조푸란 |
| DE19934952A1 (de) * | 1998-07-30 | 2000-02-03 | Novartis Ag | Cyclopentabenzofuran-Derivate |
| DE10158561A1 (de) * | 2001-11-29 | 2003-06-12 | Bayer Ag | Neue Verwendung von Cyclopentabenzofuranen |
-
2004
- 2004-05-18 DE DE102004024504A patent/DE102004024504A1/de not_active Withdrawn
-
2005
- 2005-05-14 US US11/596,907 patent/US8030347B2/en not_active Expired - Fee Related
- 2005-05-14 EP EP05747405A patent/EP1751127B1/de not_active Expired - Lifetime
- 2005-05-14 BR BRPI0510403-3A patent/BRPI0510403A/pt not_active IP Right Cessation
- 2005-05-14 JP JP2007517059A patent/JP2007538031A/ja active Pending
- 2005-05-14 CN CN2005800241153A patent/CN1989122B/zh not_active Expired - Fee Related
- 2005-05-14 CA CA2567404A patent/CA2567404C/en not_active Expired - Fee Related
- 2005-05-14 MX MXPA06013182A patent/MXPA06013182A/es active IP Right Grant
- 2005-05-14 RU RU2006144710/04A patent/RU2415847C9/ru not_active IP Right Cessation
- 2005-05-14 AU AU2005245104A patent/AU2005245104B2/en not_active Ceased
- 2005-05-14 WO PCT/EP2005/005298 patent/WO2005113529A2/de not_active Ceased
-
2006
- 2006-11-14 IL IL179257A patent/IL179257A/en not_active IP Right Cessation
- 2006-11-14 ZA ZA200609444A patent/ZA200609444B/en unknown
- 2006-11-17 KR KR1020067024170A patent/KR101215164B1/ko not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000007579A2 (de) * | 1998-08-05 | 2000-02-17 | Bayer Aktiengesellschaft | VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN |
| WO2000008007A2 (de) * | 1998-08-05 | 2000-02-17 | Bayer Aktiengesellschaft | Cyclopentabenzofuran-derivate und ihre verwendung |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005245104A1 (en) | 2005-12-01 |
| DE102004024504A1 (de) | 2006-02-16 |
| CN1989122B (zh) | 2013-07-24 |
| ZA200609444B (en) | 2008-01-30 |
| RU2006144710A (ru) | 2008-06-27 |
| JP2007538031A (ja) | 2007-12-27 |
| IL179257A0 (en) | 2007-03-08 |
| RU2415847C2 (ru) | 2011-04-10 |
| EP1751127B1 (de) | 2012-07-11 |
| US20090018113A1 (en) | 2009-01-15 |
| EP1751127A2 (de) | 2007-02-14 |
| WO2005113529A2 (de) | 2005-12-01 |
| KR20070011522A (ko) | 2007-01-24 |
| WO2005113529A3 (de) | 2006-02-09 |
| US8030347B2 (en) | 2011-10-04 |
| CA2567404C (en) | 2014-04-01 |
| IL179257A (en) | 2013-02-28 |
| AU2005245104B2 (en) | 2011-07-28 |
| CA2567404A1 (en) | 2005-12-01 |
| RU2415847C9 (ru) | 2011-08-10 |
| BRPI0510403A (pt) | 2007-10-23 |
| MXPA06013182A (es) | 2007-02-14 |
| CN1989122A (zh) | 2007-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101215164B1 (ko) | 신규 시클로펜타〔ｂ〕벤조푸란 유도체 및 이의 용도 | |
| JP7152369B2 (ja) | 複素環化合物およびその用途 | |
| EP3917616B1 (en) | Heterocyclic compounds and use thereof | |
| JP7408569B2 (ja) | 複素環化合物 | |
| JP7413261B2 (ja) | 複素環化合物およびその用途 | |
| JP7379374B2 (ja) | 複素環化合物 | |
| CN115003670A (zh) | 杂环化合物 | |
| JP7592226B1 (ja) | 複素環化合物 | |
| JP2022064180A (ja) | 複素環化合物 | |
| CN120641412A (zh) | 杂环化合物及其用途 | |
| HK1108885A (en) | Novel cylopenta[b]benzofuran derivatives and the utilization thereof | |
| HK40127534A (en) | Heterocyclic compound and use thereof | |
| EP4680611A1 (en) | Macrocyclic heterocycle compounds and use thereof | |
| HK40057687B (en) | Heterocyclic compounds and use thereof | |
| HK40057687A (en) | Heterocyclic compounds and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20151215 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20161218 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20161218 |